New inflammatory indicators for cell-based liquid biopsy: association of the circulating CD44+/CD24− non-hematopoietic rare cell phenotype with breast cancer residual disease
Issued Date
2022-01-01
Resource Type
ISSN
01715216
eISSN
14321335
Scopus ID
2-s2.0-85138059162
Pubmed ID
36100762
Journal Title
Journal of Cancer Research and Clinical Oncology
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Cancer Research and Clinical Oncology (2022)
Suggested Citation
Schreier S., Budchart P., Borwornpinyo S., Arpornwirat W., Lertsithichai P., Chirappapha P., Triampo W. New inflammatory indicators for cell-based liquid biopsy: association of the circulating CD44+/CD24− non-hematopoietic rare cell phenotype with breast cancer residual disease. Journal of Cancer Research and Clinical Oncology (2022). doi:10.1007/s00432-022-04330-5 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/83884
Title
New inflammatory indicators for cell-based liquid biopsy: association of the circulating CD44+/CD24− non-hematopoietic rare cell phenotype with breast cancer residual disease
Other Contributor(s)
Abstract
Background: Breast cancer residual disease assessment in early-stage patients has been challenging and lacks routine identification of adjuvant therapy benefit and objective measure of therapy success. Liquid biopsy assays targeting tumor-derived entities are investigated for minimal residual disease detection, yet perform low in clinical sensitivity. We propose the detection of CD44−related systemic inflammation for the assessment of residual cancer. Methods: Circulating CD44+/CD45− rare cells from healthy, noncancer- and cancer-afflicted donors were enriched by CD45 depletion and analyzed by immuno-fluorescence microscopy. CD44+ rare cell subtyping was based on cytological feature analysis and referred to as morphological index. AUC analysis was employed for identification of the most cancer-specific CD44+ subtype. Results: The EpCam−/CD44+/CD24−/CD71−/CD45−/DNA+ phenotype alludes to a distinct cell type and was found frequently at concentrations below 5 cells per 5 mL in healthy donors. Marker elevation by at least 5 × on average was observed in all afflicted cohorts. The positive predicted value for the prediction of malignancy-associated systemic inflammation of a CD44+ rare cell subtype with a higher morphological index was 87%. An outlook for the frequency of sustained inflammation in residual cancer may be given to measure 78%. Conclusion: The CD44+ rare cell and subtype denotes improvement in detection of residual cancer disease and may provide an objective and alternative measure of disease burden in early-stage breast cancer.
